Glancy Prongay & Murray LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Biogen Inc.

LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP (“GPM”) reminds investors that a class action complaint has been filed on behalf of a class comprising investors of Biogen Inc. (“Biogen” or the “Company”) (Nasdaq: BIIB) who purchased shares between January 29, 2015 and July 23, 2015 inclusive (the “Class Period”). Biogen investors have until October 19, 2015 to file a lead plaintiff motion. Investors with losses of over $1,000,000 are encouraged to contact GPM to discuss their legal rights.

On July 24, 2015 Biogen announced Second Quarter 2015 results and updated its full-year financial guidance, decreasing revenue growth to 6% to 8% based largely on revised expectations for the growth of multiple-sclerosis drug tecfidera. The Company announced that sales of tecfidera have slowed on safety concerns following last year's report of the death of a tecfidera patient. On this news, Biogen shares dropped as much as $74.34, or 19.31%, during intraday trading on July 24, 2015, thereby damaging investors.

If you purchased Biogen securities during the Class Period, or if you have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151015006292/en/

Glancy Prongay & Murray LLP, Los Angeles
Lesley Portnoy, 310-201-9150 or 888-773-9224
[email protected]
www.glancylaw.com

Source: Glancy Prongay & Murray LLP

You May Also Be Interested In

• Biogen (BIIB) PT Lowered to $300 at H.C. Wainwright
• Caravelle Lays the Groundwork for Innovative Business in Mixed Transportation and Drying Wood by Signing a MoU with the Government of Gabon
• SCS Cloud Joins the Smartsheet Aligned Partner Program